Clinical Professor of Neurology and Medical Director
Taubman Neurology
Neurology
1500 E. Medical Center Drive, 1914 Taubman Center
Ann Arbor, MI 48109-5316
[email protected]
1500 E. Medical Center Drive, 1914 Taubman Center
Ann Arbor, MI 48109-5316
Available to mentor
Praveen Dayalu
Clinical Professor
-
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Huntington Study Group SIGNAL investigators . Nat Med, 2024 Feb; 30 (2): 606Journal ArticlePublisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
DOI:10.1038/s41591-022-02070-0 PMID: 36195687 -
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D, Huntington Study Group KINECT-HD Collaborators . Lancet Neurol, 2023 Jun; 22 (6): 494 - 504.Journal ArticleSafety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
DOI:10.1016/S1474-4422(23)00127-8 PMID: 37210099 -
Sokol LL, Troost JP, Bega D, Kluger BM, Prigerson HG, Nance M, Frank S, Perlmutter JS, Dayalu P, Cella D, Carlozzi NE. Palliat Med Rep, 2023 4 (1): 79 - 88.Journal ArticleAdvance Care Planning and Health-Related Quality of Life in Huntington Disease: Results from a Multicenter National Study.
DOI:10.1089/pmr.2022.0034 PMID: 36969738 -
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Huntington Study Group SIGNAL investigators . Nat Med, 2022 Oct; 28 (10): 2183 - 2193.Journal ArticlePepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
DOI:10.1038/s41591-022-01919-8 PMID: 35941373 -
Chou KL, Dayalu P, Koeppe RA, Gilman S, Spears CC, Albin RL, Kotagal V. Mov Disord, 2022 Nov; 37 (11): 2301 - 2307.Journal ArticleSerotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
DOI:10.1002/mds.29220 PMID: 36102173 -
Furr Stimming E, Sung V, Testa C, Kostyk S, Ross CA, Samii A, Geschwind MD, Hall D, Dayalu P, Lonser R, Elder B, Larson PS, Cooper DL, Clarkin M, Ali TM, Dolmetsch RE. 2022 Sep; a95 - a95.Proceeding / Abstract / PosterJ05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)
DOI:10.1136/jnnp-2022-ehdn.255 -
Perez M, Romana A, Roberts A, Carlozzi N, Miner JA, Dayalu P, Provost EM. 2021 Sep 28; arXiv,PreprintArticulatory Coordination for Speech Motor Tracking in Huntington Disease
DOI:10.48550/arxiv.2109.13815 -
Pinarbasi ES, Liu EA, Yu Z, Kopyov O, Brown NA, Dayalu P, Lieberman AP. Acta Neuropathol, 2021 Jun; 141 (6): 979 - 981.Journal ArticleDonor-containing cortical and intraventricular glioneuronal nodules in Huntington's disease brain decades after fetal cell transplantation.
DOI:10.1007/s00401-021-02292-5 PMID: 33683397
